Original Article

You have full text access to this OnlineOpen article

The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer

  1. Johnny Kao MD1,†,*,
  2. Ha Linh Vu BA1,
  3. Eric M. Genden MD2,
  4. Bharat Mocherla MD3,
  5. Eunice E. Park MD, MPH2,
  6. Stuart Packer MD4,
  7. Peter M. Som MD3,
  8. Lale Kostakoglu MD3

Article first published online: 19 JUN 2009

DOI: 10.1002/cncr.24493

Issue

Cancer

Cancer

Volume 115, Issue 19, pages 4586–4594, 1 October 2009

Additional Information

How to Cite

Kao, J., Vu, H. L., Genden, E. M., Mocherla, B., Park, E. E., Packer, S., Som, P. M. and Kostakoglu, L. (2009), The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer, 115: 4586–4594. doi: 10.1002/cncr.24493

Author Information

  1. 1

    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York

  2. 2

    Department of Otolaryngology/Head and Neck Surgery, Mount Sinai School of Medicine, New York, New York

  3. 3

    Department of Radiology, Mount Sinai School of Medicine, New York, New York

  4. 4

    Department of Medicine, Mount Sinai School of Medicine, New York, New York

  1. †

    Fax: (212) 410-7194

*Department of Radiation Oncology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1236, New York, NY 10029

Publication History

  1. Issue published online: 17 SEP 2009
  2. Article first published online: 19 JUN 2009
  3. Manuscript Accepted: 12 FEB 2009
  4. Manuscript Revised: 11 FEB 2009
  5. Manuscript Received: 3 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (237K)

References

  • 1
    Quon A, Fischbein NJ, McDougall IR, et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007; 48( suppl 1): 58S-67S.
  • 2
    Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004; 15: 1179-1186.
  • 3
    Branstetter BF4th, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005; 235: 580-586.
  • 4
    Burri RJ, Rangaswamy B, Kostakoglu L, et al. Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2008; 71: 682-688.
  • 5
    Schoder H, Yeung HW, Gonen M, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004; 231: 65-72.
  • 6
    Kyzas PA, Evangelou E, Denaxa-Kyza D, et al. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008; 100: 712-720.
  • 7
    Lee JC, Kim JS, Lee JH, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol. 2007; 43: 686-692.
  • 8
    Ryan WR, Fee WEJr, Le QT, et al. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005; 115: 645-650.
  • 9
    Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys. 2004; 60: 1410-1418.
  • 10
    Terhaard CH, Bongers V, van Rijk PP, et al. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck. 2001; 23: 933-941.
    Direct Link:
  • 11
    Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002; 20: 4199-4208.
  • 12
    SobinLH, WittekindC, eds. TNM Classification of Malignant Tumors. 6th ed. New York, NY: John Wiley & Sons; 2002.
  • 13
    Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006; 47: 1059-1066.
  • 14
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 15
    Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008; 359: 1143–1154.
  • 16
    Kao J, Lavaf A, Teng MS, et al. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys. 2008; 71: 362-370.
  • 17
    Lavaf A, Genden EM, Cesaretti JA, et al. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer. 2008; 112: 535-543.
    Direct Link:
  • 18
    Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004; 10: 1956-1962.
  • 19
    Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol. 2006; 24: 1064-1071.
  • 20
    Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
  • 21
    Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952.
  • 22
    National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology: Head and Neck Cancer. Vol 2. Fort Washington, Pa: National Comprehensive Cancer Network; 2008. Available at http://www.nccn.org. Accessed February 2, 2009.
  • 23
    Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med. 2005; 352: 2714-2720.
  • 24
    Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008; 33: 210-222.
    Direct Link:
  • 25
    Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000; 18: 651-658.
  • 26
    Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130: 105-109; discussion 120-121.
  • 27
    Greven KM, Williams DW3rd, Keyes JWJr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994; 74: 1355-1359.
    Direct Link:
  • 28
    Horiuchi C, Taguchi T, Yoshida T, et al. Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography. Auris Nasus Larynx. 2008; 35: 103-108.
  • 29
    Kim SY, Lee SW, Nam SY, et al. The feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med. 2007; 48: 373-378.
  • 30
    McCollum AD, Burrell SC, Haddad RI, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004; 26: 890-896.
    Direct Link:
  • 31
    Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck. 2005; 27: 175-181.
    Direct Link:
  • 32
    Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg. 2007; 133: 435-440.
  • 33
    Molthoff CF, Klabbers BM, Berkhof J, et al. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol. 2007; 9: 340-347.
  • 34
    Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992; 23: 705-713.
View Full Article (HTML) Get PDF (237K)